Related Experiment Video

Updated: May 7, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.5K

Insights into targeting LKB1 in tumorigenesis

Charles B Trelford1,2, Trevor G Shepherd1,2,3,4

  • 1The Mary & John Knight Translational Ovarian Cancer Research Unit, London Regional Cancer Program, London, ON N6A 4L6, Canada.

Genes & Diseases
|December 30, 2024
PubMed

Insights

Genetic alterations in serine-threonine kinase 11 (STK11), which encodes liver kinase B1 (LKB1), play a paradoxical role in cancer. This review highlights LKB1

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Genetic alterations in serine-threonine kinase 11 (STK11) are linked to Peutz-Jeghers syndrome and tumorigenesis.
  • Liver kinase B1 (LKB1), encoded by STK11, regulates AMP-activated protein kinase (AMPK) and influences cell migration and proliferation.
  • LKB1's role in tumorigenesis is paradoxical, as it promotes cancer cell survival through autophagy and reactive oxygen species scavenging while dampening anoikis.

Purpose of the Study:

  • To review the multifaceted role of LKB1 in tumorigenesis.
  • To address the therapeutic relevance of LKB1 inhibitors in cancer treatment.
  • To highlight the challenges in validating LKB1 inhibitors due to regulatory factors.

Main Methods:

  • Literature review of STK11 and LKB1 roles in cancer.
  • Analysis of LKB1's paradoxical functions in cancer cell survival and proliferation.
  • Discussion of factors affecting LKB1 activity and inhibitor validation.

Main Results:

  • LKB1 exhibits both tumor-suppressive and pro-tumorigenic properties.
  • Targeting LKB1 pathways is a relevant strategy for cancer treatment.
  • Development of effective LKB1 inhibitors is hindered by complex regulatory mechanisms.

Conclusions:

  • Understanding LKB1's functional status is crucial before assessing pharmacological inhibitors.
  • Further research is needed to overcome challenges in LKB1 inhibitor development and validation.
  • LKB1 inhibitors hold promise for cancer therapy, necessitating a deeper understanding of LKB1 biology.
Keywords:
AMPKLKB1Peutz-Jeghers syndromeSTK11Tumor suppressor

More Related Videos

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line06:24

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line

Published on: April 11, 2025

83
Cell Population Analyses During Skin Carcinogenesis06:53

Cell Population Analyses During Skin Carcinogenesis

Published on: August 21, 2013

12.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.3K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.3K